Cost‐effective identification of Barrett's esophagus in the community: A first step towards screening

Tomonori Aoki,David I. Watson,Norma B. Bulamu

DOI: https://doi.org/10.1111/jgh.16762

2024-10-11

Journal of Gastroenterology and Hepatology

Abstract:Background and Aim The first step towards developing a screening strategy for Barrett's esophagus (BE) is the identification of individuals in the community. Currently available tools include endoscopy, less‐invasive non‐endoscopic devices, and non‐invasive risk stratification models. We evaluated the cost of potential strategies for identification of BE as a first step towards screening. Methods Two hypothetical cohorts of the general population aged ≥ 50 years with BE prevalence rates of 1.9% and 6.8% were modeled. Four potential screening tools were evaluated: (i) risk stratification based on non‐weighted clinical factors according to US/European guidelines, (ii) weighted risk stratification using algorithmic models, (iii) less‐invasive devices such as Cytosponge + trefoil factor 3 (TFF3), and (iv) endoscopy. Using a decision‐analytic model, the cost per BE case identified and the cost‐effectiveness were compared for six potential BE screening strategies based on combinations of the four screening tools; (i) + (iv), (ii) + (iv), (iii) + (iv), (i) + (iii) + (iv), (ii) + (iii) + (iv), and only (iv). Results The cost per BE case identified was lowest for the weighted risk stratification followed by Cytosponge‐TFF3 then endoscopy strategy at both 1.9% and 6.8% BE prevalences (US 3406, respectively) although it was sensitive to the cost of less‐invasive devices. This strategy was also most cost‐effective for a BE prevalence of 1.9%. At BE prevalence of 6.8%, the Cytosponge‐TFF3 followed by endoscopy strategy was most cost‐effective. Conclusions Incorporating weighted risk stratification and less‐invasive devices such as Cytosponge‐TFF3 into BE screening strategies has a potential to cost‐effectively identify BE in the community although device cost and the community prevalence of BE will impact the optimal strategy.

gastroenterology & hepatology